Pătraşcu I V
Stefan S. Nicolau, Institute of Virology, Bucharest, Romania.
Rev Roum Virol. 1990 Jan-Mar;41(1):45-51.
The pooling of five individual serum samples for the detection of human immunodeficiency virus type 1 (HIV-1) antibodies was examined to assess whether testing pooled versus individual sera was technically feasible. Detection of HIV-1 antibodies was performed using a competitive enzyme immunoassay (EIA) Wellcozyme HIV Recombinant commercially available kit. Positive, weak positive and negative sera or HIV-1 antibody from Wellcozyme HIV Recombinant, Du Pont ELISA, SERODIA HIV Mast Diagnostica and from "Stefan S. Nicolau" Institute of Virology (NIV) collection were pooled in various dilutions with control negative sera for HIV-1 antibodies. When positive sera were pooled 1:4 with negative sera, results remained reactive in the same range of positivity and when cut off-control sera were pooled 1:4 with negative sera samples remained in the cut off range. For reliability we considered cut of values of pooled sera probes an A 450 absorbance 0.2 units higher than the absorbance of cut-off-control from Wellcozyme HIV Recombinant kit B. Samples of pooled sera that have absorbance A 450 lower, equal or 0.2 units higher than the absorbance of cut off-control of Wellcozyme were considered positive and the five sera were tested as individual probes. The positive probes thus found were retested in duplicate using the original sample source. Negative samples of pooled sera do not have to be retested, this being the main advantage of this technique. Also positive sera (controls of from NIV collection) were pooled with HIV-1 antibody negative sera which were positive for rheumatoid factor (RF).(ABSTRACT TRUNCATED AT 250 WORDS)
对用于检测1型人类免疫缺陷病毒(HIV-1)抗体的5份个体血清样本进行合并检测,以评估检测合并血清与个体血清在技术上是否可行。使用竞争酶免疫测定法(EIA)Wellcozyme HIV重组商业试剂盒检测HIV-1抗体。将Wellcozyme HIV重组、杜邦酶联免疫吸附测定(ELISA)、SERODIA HIV Mast Diagnostica以及“斯特凡·S·尼科劳”病毒学研究所(NIV)收集的阳性、弱阳性和阴性血清或HIV-1抗体与HIV-1抗体阴性对照血清以不同稀释度合并。当阳性血清与阴性血清按1:4合并时,结果在相同的阳性范围内仍呈反应性,当临界对照血清与阴性血清按1:4合并时,样本仍处于临界范围内。为确保可靠性,我们将合并血清探针的临界值视为A 450吸光度比Wellcozyme HIV重组试剂盒B的临界对照吸光度高0.2个单位。合并血清样本的A 450吸光度低于、等于或比Wellcozyme临界对照吸光度高0.2个单位的样本被视为阳性,并将这5份血清作为个体探针进行检测。由此发现的阳性探针使用原始样本来源重复检测。合并血清的阴性样本无需重新检测,这是该技术的主要优点。此外,将阳性血清(来自NIV收集的对照)与类风湿因子(RF)呈阳性的HIV-1抗体阴性血清合并。(摘要截短于250字)